Pregnenolone derivatives for the treatment of Alzheimer's disease: synthesis, and in vitro inhibition of amyloid β 1–42 peptide aggregation, acetylcholinesterase and carbonic anhydrase-II
Open Access
- 2 May 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (21) , 14742-14757
Abstract
Pregnenolone-based derivatives have been synthesized to inhibit the protofibril formation in order to reduce Aβ 1–42 production and prevent its aggregation.Keywords
Funding Information
- Higher Education Commission, Pakistan (20-14513/NRPU/R&D/HEC/2021 2021)
This publication has 69 references indexed in Scilit:
- Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (Aβ) axis in amyloidogenic and non-amyloidogenic pathways: A time outside the tunnelAgeing Research Reviews, 2023
- Recent Progress in the Treatment Strategies for Alzheimer’s Disease2023
- Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agentsBioorganic Chemistry, 2020
- Design, synthesis, in-vitro thymidine phosphorylase inhibition, in-vivo antiangiogenic and in-silico studies of C-6 substituted dihydropyrimidinesBioorganic Chemistry, 2018
- Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality2014
- Natural Compounds May Open New Routes to Treatment of Amyloid DiseasesNeurotherapeutics, 2013
- Carbonic anhydrase II-based metal ion sensing: Advances and new perspectivesBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Neurosteroids2010
- Sulfamates and their therapeutic potentialMedicinal Research Reviews, 2004
- Acetylcholinesterase promotes the aggregation of amyloid-β-peptide fragments by forming a complex with the growing fibrils 1 1Edited by A. R. FershtJournal of Molecular Biology, 1997